313 related articles for article (PubMed ID: 19168136)
1. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
3. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
[TBL] [Abstract][Full Text] [Related]
4. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
Petr GT; Schultheis LA; Hussey KC; Sun Y; Dubinsky JM; Aoki C; Rosenberg PA
Eur J Neurosci; 2013 Aug; 38(3):2477-90. PubMed ID: 23586612
[TBL] [Abstract][Full Text] [Related]
7. Dearth of glutamate transporters contributes to striatal excitotoxicity.
Brustovetsky T; Purl K; Young A; Shimizu K; Dubinsky JM
Exp Neurol; 2004 Oct; 189(2):222-30. PubMed ID: 15380474
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.
Klapstein GJ; Levine MS
J Neurophysiol; 2005 Feb; 93(2):758-65. PubMed ID: 15371492
[TBL] [Abstract][Full Text] [Related]
9. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.
Behrens PF; Franz P; Woodman B; Lindenberg KS; Landwehrmeyer GB
Brain; 2002 Aug; 125(Pt 8):1908-22. PubMed ID: 12135980
[TBL] [Abstract][Full Text] [Related]
10. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
[TBL] [Abstract][Full Text] [Related]
11. Methylmercury alters the in vitro uptake of glutamate in GLAST- and GLT-1-transfected mutant CHO-K1 cells.
Mutkus L; Aschner JL; Syversen T; Aschner M
Biol Trace Elem Res; 2005 Dec; 107(3):231-45. PubMed ID: 16286679
[TBL] [Abstract][Full Text] [Related]
12. Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum.
Nickell J; Salvatore MF; Pomerleau F; Apparsundaram S; Gerhardt GA
Neurobiol Aging; 2007 Nov; 28(11):1737-48. PubMed ID: 16959378
[TBL] [Abstract][Full Text] [Related]
13. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
André VM; Cepeda C; Venegas A; Gomez Y; Levine MS
J Neurophysiol; 2006 Apr; 95(4):2108-19. PubMed ID: 16381805
[TBL] [Abstract][Full Text] [Related]
14. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.
Rebec GV; Conroy SK; Barton SJ
Neuroscience; 2006; 137(1):327-36. PubMed ID: 16257492
[TBL] [Abstract][Full Text] [Related]
15. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
Ariano MA; Wagle N; Grissell AE
J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
[TBL] [Abstract][Full Text] [Related]
16. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.
Desplats PA; Kass KE; Gilmartin T; Stanwood GD; Woodward EL; Head SR; Sutcliffe JG; Thomas EA
J Neurochem; 2006 Feb; 96(3):743-57. PubMed ID: 16405510
[TBL] [Abstract][Full Text] [Related]
17. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
[TBL] [Abstract][Full Text] [Related]
18. Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice.
Estrada-Sánchez AM; Montiel T; Massieu L
Neurochem Res; 2010 Aug; 35(8):1156-63. PubMed ID: 20401690
[TBL] [Abstract][Full Text] [Related]
19. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
[TBL] [Abstract][Full Text] [Related]
20. Subcellular localization of the glutamate transporters GLAST and GLT at the neuromuscular junction in rodents.
Rinholm JE; Slettaløkken G; Marcaggi P; Skare Ø; Storm-Mathisen J; Bergersen LH
Neuroscience; 2007 Mar; 145(2):579-91. PubMed ID: 17289278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
